trademark for preparations of butabarbital, a barbiturate.


A fast-acting sedative/hypnotic of intermediate duration of action.
Adverse effects
Drowsiness, insomnia, nightmares, headaches, dizziness, depression, excitability, restlessness, nausea, vomiting, constipation, dyspnoea.


Butabarbital, see there.
Mentioned in ?
References in periodicals archive ?
The label change affects drugs including Zolpidem, marketed as Ambien/Ambien CR by Sanofi-Aventis; butabarbital, marketed as Butisol Sodium by Medpointe Pharmaceuticals HLC; flurazepam, marketed as Dalmane by Valeant Pharmaceuticals; quazepam, marketed as Doral by Questcor Pharmaceuticals; triazolam, marketed as Halcion by Pharmacia & Upjohn Inc.
Amytal (amobarbial), barbs, bluebirds, blues, butisol (butabarbital), downers, goofballs, luminal (phenobarbital), 'ludes, 714s (methaqualone), seconal (secobarbital), nembutal (pentobarbital), tooties, yellow jackets
Antianxiety and Hypnotic Agents -- Librium, Valium, Dalmane, Miltown/Equanil, Tranxene, Paxipam, Centrax, Klonopin, Ativan, ProSom, Doral, Serax, Xanax, Halcion, chloral hydrate, Doriden, Noludar, Placidyl, Seconal, Nembutal, Amytal, Tuinal, Butisol, phenobarbital